ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

VXRT Vaxart Inc

0.74
0.0394 (5.62%)
03 5월(5) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Vaxart Inc VXRT 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.0394 5.62% 0.74 09:00:00
개장가 저가 고가 종가 전일 종가
0.7182 0.69 0.7469 0.749 0.7006
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
30/04/202421:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/03/202421:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/03/202421:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
15/03/202405:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/03/202420:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
07/03/202422:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
06/03/202423:23EDGAR2Form 8-K - Current report
06/03/202422:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
01/03/202406:30EDGAR2Form 8-K - Current report
16/02/202406:10EDGAR2Form 8-K - Current report
14/02/202407:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/02/202422:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
03/02/202406:49EDGAR2Form 8-K/A - Current report: [Amend]
20/01/202407:14EDGAR2Form 8-K - Current report
20/01/202406:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
19/01/202422:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
17/01/202407:18EDGAR2Form 8-K - Current report
16/01/202423:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
16/01/202423:22GLOBEVaxart, Inc. Announces Management Change
16/01/202423:19EDGAR2Form 8-K - Current report
21/12/202322:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
03/11/202305:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202305:11EDGAR2Form 8-K - Current report
03/11/202305:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202321:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202321:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
24/10/202306:09EDGAR2Form 8-K/A - Current report: [Amend]
24/10/202306:01EDGAR2Form 8-K - Current report
11/10/202321:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/09/202321:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
07/09/202305:43EDGAR2Form 8-K - Current report
07/09/202305:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
04/08/202305:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/08/202305:20EDGAR2Form 8-K - Current report
04/08/202305:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
02/08/202310:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/08/202310:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/08/202310:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/08/202310:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/08/202309:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/07/202321:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
27/07/202305:20EDGAR2Form 8-K - Current report
11/07/202305:12EDGAR2Form 8-K - Current report
06/07/202321:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
29/06/202305:22EDGAR2Form 8-K - Current report
27/06/202305:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
22/06/202305:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
07/06/202322:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
07/06/202305:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
06/06/202321:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..

최근 히스토리

Delayed Upgrade Clock